Zimmer Biomet has acquired Pacira BioSciences, Inc. for $140.0M. This strategic acquisition integrates Pacira BioSciences, Inc., a pioneer in non-opioid pain management, into Zimmer Biomet, a leading medical technology company. Pacira, founded in 2006, has been dedicated to transforming how pain is treated and experienced through its innovative, long-acting non-opioid therapies. The acquisition highlights Zimmer Biomet's focus on expanding its portfolio with advanced solutions designed to enhance patient care pathways and improve surgical recovery experiences.
Pacira BioSciences has established itself at the forefront of addressing unmet needs in pain management, developing advanced options that challenge the status quo of care. Guided by its belief that better is possible, the company has focused on empowering patients and clinicians with therapies that reimagine life beyond pain. With a team of over 800 dedicated employees, Pacira has consistently pursued innovation, from pioneering targeted non-opioid therapies to exploring cutting-edge advancements such as gene therapy, further solidifying its position in the evolving landscape of pain treatment.
This acquisition is expected to generate significant synergies by integrating Pacira's specialized non-opioid pain management solutions into Zimmer Biomet's broader offerings. The combination aims to provide more comprehensive options for clinicians and patients, particularly in areas where non-opioid alternatives are increasingly sought after to manage post-operative pain. By leveraging Zimmer Biomet's established market presence and resources, Pacira's innovative therapies are anticipated to achieve wider adoption, enhancing patient outcomes and setting new standards in pain management. The combined entity is poised to strengthen its market position and continue advancing solutions that improve lives beyond pain.